Interchange Capital Partners LLC Purchases 635 Shares of Eli Lilly and Company (NYSE:LLY)

Interchange Capital Partners LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 157.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,038 shares of the company’s stock after acquiring an additional 635 shares during the quarter. Interchange Capital Partners LLC’s holdings in Eli Lilly and Company were worth $940,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Essex Financial Services Inc. lifted its holdings in shares of Eli Lilly and Company by 5.8% during the second quarter. Essex Financial Services Inc. now owns 28,183 shares of the company’s stock valued at $25,517,000 after acquiring an additional 1,556 shares during the period. Turtle Creek Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 4.3% during the second quarter. Turtle Creek Wealth Advisors LLC now owns 5,157 shares of the company’s stock valued at $4,669,000 after acquiring an additional 212 shares during the period. Hanseatic Management Services Inc. lifted its holdings in shares of Eli Lilly and Company by 1.6% during the second quarter. Hanseatic Management Services Inc. now owns 1,321 shares of the company’s stock valued at $1,196,000 after acquiring an additional 21 shares during the period. Elk River Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 3.3% in the second quarter. Elk River Wealth Management LLC now owns 8,958 shares of the company’s stock valued at $8,110,000 after buying an additional 287 shares in the last quarter. Finally, Aptus Capital Advisors LLC increased its stake in shares of Eli Lilly and Company by 22.0% in the second quarter. Aptus Capital Advisors LLC now owns 30,297 shares of the company’s stock valued at $27,431,000 after buying an additional 5,454 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 2.1 %

Shares of NYSE:LLY traded up $19.82 during trading on Friday, hitting $960.02. 2,555,073 shares of the company were exchanged, compared to its average volume of 3,625,430. The stock has a market cap of $912.43 billion, a price-to-earnings ratio of 141.39, a P/E/G ratio of 2.91 and a beta of 0.41. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The firm has a fifty day moving average price of $892.64 and a two-hundred day moving average price of $822.08. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, research analysts anticipate that Eli Lilly and Company will post 16.51 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is 76.58%.

Analysts Set New Price Targets

LLY has been the subject of a number of research reports. Jefferies Financial Group raised their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Thursday, July 11th. Berenberg Bank raised their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Barclays lifted their price objective on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Finally, Truist Financial reiterated a “buy” rating and issued a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Two research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $961.76.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the sale, the insider now owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The disclosure for this sale can be found here. Insiders have sold a total of 1,097,883 shares of company stock valued at $972,022,568 in the last ninety days. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.